• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ionis reports first quarter 2023 financial results

    5/3/23 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IONS alert in real time by email

    QALSODY approved for SOD1-ALS; MAA under review in EU

    Reported positive Phase 3 eplontersen ATTRv-PN data; December 22, 2023 PDUFA date

    On track to achieve 2023 financial guidance

    CARLSBAD, Calif., May 3, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the first quarter of 2023. Financial results are summarized below:

    Ionis logo with tagline (PRNewsfoto/Ionis Pharmaceuticals, Inc.)





    Three months

    ended

    March 31,







    2023



    2022







    (amounts in millions)



    Total revenue



    $131



    $142



    Operating expenses



    $245



    $199



    Operating expenses on a non-GAAP basis



    $218



    $173



    Loss from operations



    ($114)



    ($57)



    Loss from operations on a non-GAAP basis



    ($87)



    ($31)



    Financial Highlights

    • Revenue for the first quarter of 2023 was in line with expectations and included revenue from numerous diverse sources
    • Operating expenses increased in the first quarter of 2023 compared to the prior year as planned, reflecting investments in advancing Ionis' pipeline, technology and go-to-market activities for eplontersen, olezarsen and donidalorsen
    • Cash and short-term investments of $2.3 billion at March 31, 2023 enables continued investment in creating future growth opportunities
    • Reaffirmed 2023 financial guidance

    "2023 is off to a strong start. With QALSODY's approval, it joins SPINRAZA as a new groundbreaking medicine to treat a devastating neurological disease, further validating our RNA-targeting therapeutic platform. We also achieved another important milestone with our recent positive eplontersen Phase 3 data. We believe the positive efficacy and safety data, and the attractive self-administered dosing profile, position eplontersen to be an important treatment for ATTRv-PN patients, who today are underserved. We look forward to the first potential approval of eplontersen in the U.S. in December," said Brett P. Monia, Ph.D., chief executive officer of Ionis. "In addition, we further expanded our industry-leading late-stage pipeline to seven programs across nine indications following the start of GSK's bepirovirsen hepatitis B program. In the second half, we plan to report results from our olezarsen Phase 3 FCS study, which if positive, positions us for our first independent commercial launch. These recent achievements, together with our upcoming milestones, continue to build value for Ionis stakeholders."

    Recent Late-Stage Pipeline Highlights

    • FDA granted Biogen accelerated approval of QALSODY (tofersen) for patients with SOD1-ALS
    • FDA accepted eplontersen NDA for patients with polyneuropathy caused by hereditary TTR amyloidosis (ATTRv-PN) with a PDUFA date of December 22, 2023
    • Presented positive week-35 and week-66 data from the Phase 3 NEURO-TTRansform study of eplontersen in patients with ATTRv-PN
    • GSK advanced bepirovirsen into Phase 3 development in patients with chronic hepatitis B

    Recent Additional Pipeline Updates

    • Biogen presented data demonstrating IONIS-MAPTRx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
    • Continued to focus R&D efforts by discontinuing two programs that did not meet Ionis' target product profile, cimdelirsen for acromegaly and sapablursen for beta-thalassemia. Ionis continues to advance the Phase 2 sapablursen study for polycythemia vera

    First Quarter 2023 Financial Results

    "Our first quarter results were in line with our expectations. We generated meaningful revenue while continuing to invest in key growth opportunities across our business. These results keep us on track to achieve our 2023 financial guidance," said Elizabeth L. Hougen, chief financial officer of Ionis. "We plan to continue investing in areas with the greatest potential to drive growth. As such, we expect our investments to grow modestly as we advance and expand our late-stage pipeline and move our near-term commercial opportunities toward the market. Additionally, as we keep more programs for ourselves, we expect a greater proportion of commercial revenues compared to R&D revenues, and our commercial revenues to be the primary driver of future revenue growth."

    Revenue

    Ionis' revenue was comprised of the following:





    Three months ended









    March 31,









    2023



    2022





    Revenue:



    (amounts in millions)





         Commercial revenue:













    SPINRAZA royalties



    $50



    $54





    TEGSEDI and WAYLIVRA revenue, net



    7



    6





    Licensing and royalty revenue



    11



    12





    Total commercial revenue



    68



    72





    Research and development revenue:













    Amortization from upfront payments



    16



    17





    Milestone payments



    23



    27





    License fees



    -



    2





    Other services



    -



    4





    Collaborative agreement revenue



    39



    50





    Eplontersen joint development revenue



    24



    20





    Total research and development revenue



    63



    70





    Total revenue



    $131



    $142





    Ionis continued to derive its revenue for the first quarter of 2023 from diverse sources, with approximately half coming from commercial products and half from numerous partnered programs. Commercial revenue for the first quarter of 2023 included $50 million from SPINRAZA royalties. Global SPINRAZA product sales of $443 million decreased six percent in the first quarter of 2023, compared to the same period last year primarily due to the impact from foreign currency, fewer new patient starts in the U.S. and channel dynamics.

    R&D revenue for the first quarter of 2023 included $24 million from AstraZeneca for its share of the global Phase 3 development costs for eplontersen, $20 million from Biogen for advancing several neurology disease programs and $15 million from GSK for advancing bepirovirsen into Phase 3 development. Already in the second quarter, the Company earned $16 million in a milestone payment from Biogen when QALSODY was approved in the U.S.

    Operating Expenses

    Ionis' operating expenses increased in the first quarter of 2023 compared to the same period in 2022, consistent with expectations. As Ionis advanced its robust pipeline, study costs increased as most of the Company's Phase 3 studies were either fully enrolled or approaching full enrollment resulting in higher R&D expenses year over year. Additionally, as Ionis prepares to launch eplontersen, olezarsen and donidalorsen, the Company's SG&A expenses also increased year over year.

    Balance Sheet

    As of March 31, 2023, Ionis' cash, cash equivalents and short-term investments increased to $2.3 billion compared to $2.0 billion at December 31, 2022 primarily due to the $500 million Ionis received from Royalty Pharma in January 2023. Ionis' working capital also increased over the same period primarily due to the Company's higher cash and short-term investments balance. Additionally, the Company recorded a long-term liability for future royalties due to Royalty Pharma in the first quarter of 2023.

    Webcast

    Management will host a conference call and webcast to discuss Ionis' first quarter 2023 results at 11:30 a.m. Eastern time on Wednesday, May 3, 2023. Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address. To access the Company's first quarter 2023 earnings slides click here.

    About Ionis Pharmaceuticals, Inc.

    For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies. 

    To learn more about Ionis visit www.ionispharma.com or follow us on Twitter @ionispharma.

    Ionis' Forward-looking Statement

    This press release includes forward-looking statements regarding Ionis' business, financial guidance and the therapeutic and commercial potential of QALSODY (tofersen), SPINRAZA (nusinersen), TEGSEDI (inotersen), WAYLIVRA (volanesorsen), eplontersen, olezarsen, donidalorsen, ION363, pelacarsen, bepirovirsen, Ionis' technologies and Ionis' other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2022, which is on file with the Securities and Exchange Commission. Copies of this and other documents are available from the Company.

    In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.

    Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea Therapeutics, Inc. TEGSEDI® is a registered trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. QALSODY™ is a trademark of Biogen. SPINRAZA® is a registered trademark of Biogen.

     

    IONIS PHARMACEUTICALS, INC.

    SELECTED FINANCIAL INFORMATION

    Condensed Consolidated Statements of Operations

    (In Millions, Except Per Share Data)







    Three months ended,









    March 31,









    2023



    2022









    (unaudited)



    Revenue:













         Commercial revenue:













    SPINRAZA royalties



    $50



    $54





    TEGSEDI and WAYLIVRA revenue, net



    7



    6





    Licensing and royalty revenue



    11



    12





    Total commercial revenue



    68



    72





    Research and development revenue:













    Collaborative agreement revenue



    39



    50





    Eplontersen joint development revenue



    24



    20





    Total research and development revenue



    63



    70





    Total revenue



    131



    142





    Expenses:













           Cost of sales



    1



    4





        Research, development and patent



    198



    161





        Selling, general and administrative



    46



    34





    Total operating expenses



    245



    199





    Loss from operations



    (114)



    (57)



















    Other income (expense):

    Interest expense related to sale of future royalties



    (16)



    -



    Other income (expense), net



    17



    (7)





    Loss before income tax expense



    (113)



    (64)



















    Income tax expense



    (11)



    (1)



















    Net loss



    ($124)



    ($65)































    Basic and diluted net loss per share



    ($0.87)



    ($0.46)





    Shares used in computing basic and diluted net loss per share



    143



    142





     

    IONIS PHARMACEUTICALS, INC.

    Reconciliation of GAAP to Non-GAAP Basis:

    Condensed Consolidated Operating Expenses, Loss From Operations, and Net Loss

    (In Millions)





    Three months

    ended

    March 31,







    2023



    2022





    (unaudited)

    As reported research, development and patent expenses according to GAAP



    $198



    $161

        Excluding compensation expense related to equity awards      



    (20)



    (19)

    Non-GAAP research, development and patent expenses



    $178



    $142











    As reported selling, general and administrative expenses according to GAAP



    $46



    $34

        Excluding compensation expense related to equity awards      



    (7)



    (7)

    Non-GAAP selling, general and administrative expenses



    $39



    $27











    As reported operating expenses according to GAAP



    $245



    $199

    Excluding compensation expense related to equity awards      



    (27)



    (26)

    Non-GAAP operating expenses



    $218



    $173











    As reported loss from operations according to GAAP



    ($114)



    ($57)

        Excluding compensation expense related to equity awards      



    (27)



    (26)

    Non-GAAP loss from operations



    ($87)



    ($31)











    As reported net loss according to GAAP



    ($124)



    ($65)

        Excluding compensation expense related to equity awards and related tax effects      



    (27)



    (26)

    Non-GAAP net loss



    ($97)



    ($39)

    Reconciliation of GAAP to Non-GAAP Basis

    As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis' non-GAAP results is consistent with how Ionis' management internally evaluates the performance of its operations.

    IONIS PHARMACEUTICALS, INC.

    Condensed Consolidated Balance Sheets

    (In Millions)

     


















    March 31,



    December 31,







    2023



    2022







    (unaudited)







    Assets:











      Cash, cash equivalents and short-term investments



    $2,347



    $1,987



      Contracts receivable



    14



    26



      Other current assets



    182



    190



      Property, plant and equipment, net



    85



    74



      Right-of-use assets



    179



    182



      Other assets



    78



    75



         Total assets



    $2,885



    $2,534















    Liabilities and stockholders' equity:











      Other current liabilities



    $167



    $221



      Current portion of deferred contract revenue



    92



    91



      0% convertible senior notes, net



    623



    622



      0.125% convertible senior notes, net



    545



    545



      Liability related to sale of future royalties, net



    505



    -



      Long-term lease liabilities



    177



    178



      Long-term obligations, less current portion



    16



    16



      Long-term deferred contract revenue



    273



    288



      Total stockholders' equity



    487



    573



        Total liabilities and stockholders' equity



    $2,885



    $2,534



    2023 Key Value Driving Events(1) 

    Regulatory Actions

    Program

    Indication

    Regulatory Action

    QALSODY

    SOD1-ALS

    NDA approval

    (achieved)

    EU approval2

    Eplontersen (TTR)

    ATTRv polyneuropathy

    NDA approval

    OUS filings



    Key Clinical Achievements

    Program

    Indication

    Event

    Eplontersen (TTR)

    ATTRv polyneuropathy

    Phase 3 data (week 35

    & 66) (achieved)

    Olezarsen

    FCS

    Phase 3 data

    Eplontersen (TTR)

    ATTR cardiomyopathy

    Phase 3 full enrollment

    Donidalorsen (PKK)

    HAE

    Phase 3 full enrollment



    Phase 3 Initiations

    Program

    Indication

    Timing

    Bepirovirsen (HBV)

    Hepatitis B virus infection

    H1:23 (achieved)

    IONIS-FB-LRx

    Immunoglobulin A

    nephropathy

    H1:23



    (1)  Timing expectations based on current assumptions and subject to change.

    (2)  CHMP opinion anticipated in Q4:2023.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-reports-first-quarter-2023-financial-results-301813913.html

    SOURCE Ionis Pharmaceuticals, Inc.

    Get the next $IONS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IONS

    DatePrice TargetRatingAnalyst
    7/1/2025$57.00Equal Weight → Overweight
    Barclays
    4/7/2025$45.00Buy
    H.C. Wainwright
    3/31/2025$39.00Neutral
    Redburn Atlantic
    8/2/2024$67.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/24/2024$53.00 → $62.00Market Perform → Outperform
    Leerink Partners
    7/16/2024$29.00 → $75.00Buy
    Jefferies
    6/14/2024$44.00Underperform → Mkt Perform
    Bernstein
    4/10/2024$58.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $IONS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Loscalzo Joseph converted options into 4,079 shares, increasing direct ownership by 13% to 36,330 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/17/25 4:59:28 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Parshall B Lynne converted options into 4,079 shares, increasing direct ownership by 5% to 91,344 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/17/25 4:54:25 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wender Joseph H converted options into 4,079 shares (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      7/17/25 4:54:31 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      5/2/25 4:38:26 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      12/26/24 4:57:52 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    SEC Filings

    See more
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      6/12/25 9:00:44 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      6/10/25 6:02:16 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      5/19/25 7:18:21 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

      – Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZA – – European Commission decision expected by Q4 2025 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Sobi® today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of TRYNGOLZA® (olezarsen) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The positive opinion is now referred to the European Commission (EC) for an approval decision, which is expected by Q4 2

      7/25/25 7:15:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

      – Patients switched to donidalorsen without increased breakthrough attacks and experienced further reductions in mean attack rate from baseline – – 84% of patients surveyed preferred donidalorsen over their prior treatment – – Donidalorsen is currently under review with the U.S. FDA as a potential first-in-class prophylactic treatment for HAE; PDUFA date August 21 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that positive results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients with hereditary angioedema (HAE) were published in The Journal of Allergy and Clinical Immunology (JACI) In Practice. Results indicate that patients who switched to

      7/21/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis to hold second quarter 2025 financial results webcast

      Webcast scheduled for Wednesday, July 30 at 11:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Wednesday, July 30th at 11:30 a.m. Eastern Time to discuss its second quarter 2025 financial results and progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and

      7/16/25 7:05:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ionis Pharma upgraded by Barclays with a new price target

      Barclays upgraded Ionis Pharma from Equal Weight to Overweight and set a new price target of $57.00

      7/1/25 8:12:05 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Ionis Pharma with a new price target

      H.C. Wainwright initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $45.00

      4/7/25 8:43:57 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redburn Atlantic initiated coverage on Ionis Pharma with a new price target

      Redburn Atlantic initiated coverage of Ionis Pharma with a rating of Neutral and set a new price target of $39.00

      3/31/25 8:13:04 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Financials

    Live finance-specific insights

    See more
    • Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

      Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

      6/25/25 7:30:37 AM ET
      $BIIB
      $IONS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ionis reports first quarter 2025 financial results

      - Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025. "With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "We look forward to continued m

      4/30/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

      Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) expected in Q3 2024 PRAX-628 Phase 2/3 POWER1 study to initiate in Q4 2024 Initiation of additional Phase 2 study (RADIANT) for PRAX-628 in focal and generalized epilepsy in 2H 2024, with topline results expected in 1H 2025 Cash and investments of $434 million as of June 30, 2024, maintains runway into 2027 BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a

      8/13/24 7:00:00 AM ET
      $IONS
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Leadership Updates

    Live Leadership Updates

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Ionis announces the appointment of Michael Yang to Board of Directors

      CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and B

      12/14/23 4:05:00 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/14/24 8:34:57 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/14/24 1:28:29 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

      SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/8/24 10:52:38 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care